R&D | Cutting-edge science and innovative research

R&D

LSX2026: Non-opioid pain relief and pharma positivity, with ...

Mike Cooke, CEO of AmacaThera, spoke with pharmaphorum at the LSX World Congress, including about non-opioid pain relief.

News

IDEAYA/Servier PKC drug aces uveal melanoma trial

Servier $210m bet on IDEAYA's uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.

News

Data backs GSK's ovarian cancer blockbuster hopes

GSK's B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme.

R&D

Scientist using manual and AI methods in lab

From in silico to in vivo: Why development strategy now dete...

As discovery becomes faster and more accessible, the differentiator shifts downstream.

R&D

handshake and corporate body in the background of

Changing Faces: Pharma and biotech, March 2026

A broad mix of senior leadership and scientific and commercial appointments shaped last month’s pharma and biotech hiring activity.

News

BioNTech to set up mRNA manufacturing site in Singapore

BioNTech has said it plans to set up a regional base and new manufacturing site in Singapore so that the biotech can keep pace with demand for its mRNA-based coronavirus vaccine and pipelin

News

Coronavirus won't be circulating in UK by August, says outgo...

Coronavirus won’t be circulating in the UK by August, according to the outgoing chief of the country’s vaccine rollout scheme, Dr Clive Dix.

Views & Analysis

Where-next-for-patient-centricity-in-pharma

Why relationships are key in rare disease patient engagement

Real-world data is a vital part of rare disease drug development, but to get a true picture of patients’ unmet needs pharma should take a broader view of their lived experiences, says Xperi

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

R&D

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

IDEAYA/Servier PKC drug aces uveal melanoma trial

Servier $210m bet on IDEAYA's uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.

News

Data backs GSK's ovarian cancer blockbuster hopes

GSK's B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme.

Press Releases

Views & Analysis

Touring Chiesi's vision for the future at the new Biotech Ce...

Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure – black-painted and as yet under construction, gigantic cranes and all – th

News

Vir awarded $1 billion multi-year BARDA influenza contract

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an

Views & Analysis

R&D

LSX2026: Non-opioid pain relief and pharma positivity, with ...

Mike Cooke, CEO of AmacaThera, spoke with pharmaphorum at the LSX World Congress, including about non-opioid pain relief.

R&D

From in silico to in vivo: Why development strategy now dete...

As discovery becomes faster and more accessible, the differentiator shifts downstream.

R&D

Changing Faces: Pharma and biotech, March 2026

A broad mix of senior leadership and scientific and commercial appointments shaped last month’s pharma and biotech hiring activity.

Deep Dive

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

Beyond obesity: How GLP-1s are changing the game for hundred...

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

R&D

evolution of clinical research in the UK

Sponsored

The evolution of clinical research: Embracing new delivery m...

The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin

Podcasts

R&D

pharmaphorum podcast Episode 253, Lance Baldo, Beacon Therapeutics

Looking to gene therapy for ocular diseases, with Lance Bald...

Lance Baldo, CEO of Beacon Therapeutics, discusses the transformative power of gene therapy to deliver meaningful outcomes for severe ocular diseases.

R&D

pharmaphorum podcast Episode 250, Rob DiCicco, Transcelerate

Making AI work where it matters, with Rob DiCicco

Rob DiCicco, vice president of portfolio management at Transcelerate Biopharma Inc, discusses barriers and the breakthroughs in making AI work.

R&D

pharmaphorum podcast Episode 249, Michelle Werner, Alltrna

Treating genetic disease at scale with tRNA, with Michelle W...

Michelle Werner, Director of Alltrna, discusses her company’s approach of leveraging transfer RNA (tRNA) to shift the paradigm in genetic medicine.

Video

R&D

LSX2026: Non-opioid pain relief and pharma positivity, with ...

Mike Cooke, CEO of AmacaThera, spoke with pharmaphorum at the LSX World Congress, including about non-opioid pain relief.

R&D

Interview at LSX 2026 with Alexander Gebauer

LSX2026: On a therapeutic vision for ocular disease, with Al...

Alexander Gebauer, co-founder & executive chairman of Galimedix Therapeutics, discusses transforming treatment of major neurodegenerative eye diseases

R&D

Interview at BIO-Europe 2026 with Robert Jacks

BIO-Europe Spring 2026: In conversation with Robert Jacks

White Papers

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.

R&D